Lantheus: A Strong Start to 2026, But the Real Story Is the PYLARIFY TRUVU Transition

Lantheus Holdings reported a robust first quarter, with revenue of $377.3 million, up 1.2% year-over-year, or 8.6% when excluding the divested SPECT business. The company reiterated its full-year guidance, signaling confidence in its 2026 plan even as it prepares for a pivotal transition of its flagship prostate cancer imaging franchise. The quarter was punctuated by two regulatory milestones: the FDA approval of PYLARIFY TRUVU and the tentative approval of tentative approval for PNT2003, setting the stage for a potential wave of growth beginning in 2027.

Regulatory Milestones and the TRUVU Transition

The most significant development was the March 6 approval of PYLARIFY TRUVU, a new formulation of the company's PSMA PET imaging agent. CEO Mary Heino described the value proposition: “This creates the potential to serve more patients and support a broader geographic reach.” — Mary Heino, CEO and Executive Chairperson · 2026-05-07 The company plans a site-by-site conversion beginning in Q4 2026, carefully timed to align with reimbursement coding and payer readiness. As Heino emphasized, “We plan to begin that conversion in Q4 of this year.” — Mary Heino, CEO and Executive Chairperson · 2026-05-07 This transition is critical because TRUVU, with higher batch sizes and enhanced stability, is expected to improve supply flexibility and potentially reset the reimbursement dynamic—particularly through transitional pass-through status and a 340B price reset. The company's prior calls laid the groundwork: in February 2026, Heino noted, “We have chosen a regional-based rollout, allowing for duplicity so that we absolutely still have service in place to flip from PYLARIFY to our new formulation.” — Mary Anne Heino, CEO and Executive Chairperson (Interim) · 2026-02-26

In the first quarter, we accomplished what we set out to do. PYLARIFY, NEUROCEQ and DEFINITY all performed well, and we achieved two important regulatory milestones with the FDA approval of PYLARIFY TRUVU and tentative approval of PNT2003.

The company is also progressing PNT2003, a radio equivalent to Lutathera for neuroendocrine tumors, which received tentative approval in March. The final approval hinges on the expiration of the Hatch-Waxman stay and related legal proceedings, with a launch expected once coding and reimbursement are secured. Additionally, MK-6240, a tau-targeted PET agent for Alzheimer's, has a PDUFA date of August 13, further expanding the pipeline.

Commercial Execution Across Three Pillars

Amanda Morgan highlighted the balanced performance: “First quarter performance demonstrated continued commercial execution across our portfolio with solid volume growth and disciplined performance across each of our three core products.” — Amanda Morgan, Chief Commercial Officer · 2026-05-07 PYLARIFY delivered U.S. volume growth of approximately 5.8% year-over-year, with stable net ASP and volume sequentially despite competitive pressure. NEURACEQ generated $35.4 million, up 14.3% sequentially, and is now the second most utilized beta-amyloid agent, benefiting from expanded manufacturing footprint and deeper account penetration. DEFINITY, the cardiology product, grew 6.8% to $84.6 million, underpinned by over 80% market share.

These results underscore the durability of the franchise, but the company is deliberately managing expectations. CFO Bob Marshall noted, “Revenue for the first quarter was $377.3 million, an increase of 1.2% compared to the prior year and increased 8.6% when adjusted to exclude $25.2 million of spec revenues from the same period prior year, which was divested on January 1.” — Robert Marshall, CFO · 2026-05-07 Despite the beat, guidance remained unchanged—revenue of $1.4–1.45 billion and adjusted EPS of $5–5.25—reflecting a cautious outlook due to the imminent CEO transition and persistent competitive dynamics in the PSMA PET market. This prudence is consistent with prior quarters, where management emphasized discipline over aggressive guidance.

Financial Trends and Strategic Focus

Gross margin held steady at 67% on an adjusted basis, aided by the SPECT divestiture and volume growth, though offset by PYLARIFY pricing headwinds and the dilutive impact of recent acquisitions. The company generated $125.1 million in operating cash flow and $121.9 million in free cash flow, up materially year-over-year. Total Revenue reached $377 million, with yoy growth of 1% reported but 8.6% on an adjusted basis. This financial strength supports ongoing investment in the radio diagnostic pipeline and the potential for capital returns.

The strategic narrative is unmistakable: Lantheus is doubling down on radio diagnostics while evaluating alternatives for its radiotherapeutic assets. The company's focus on PSMA Pet imaging, coupled with the Alzheimer's franchise (NEUROCEQ), positions it for sustained growth. As Heino summarized, "We are making deliberate choices about where we focus our commercial efforts and deploying capital so we're positioned to deliver solid results in 2026 and accelerate growth in 2027." The market appears to be listening—the stock has rallied 24% over the last 90 days, recovering from earlier drawdowns, yet still trades at a discount to its peak valuation.

In conclusion, Lantheus delivered a clean beat, but the real signal is the disciplined execution of a multi-product launch strategy. The TRUVU conversion and PNT2003 approval could inflect growth in 2027, making this a pivotal year for the company's long-term trajectory.